The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes of first-line anti-EGFR antibody versus anti-VEGF therapy stratified by DNA methylation status in right-sided metastatic colorectal cancer: A propensity score weighting analysis.
 
Takeshi Suto
No Relationships to Disclose
 
Kozo Kataoka
Honoraria - Guardant Health; Lilly; Merck; Takeda
Research Funding - Nakatani Foundation; Sysmex
 
Keita Mori
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Welby
 
Kunihiro Fushiki
No Relationships to Disclose
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Mitsuru Yokota
No Relationships to Disclose
 
Junichi Mazaki
No Relationships to Disclose
 
Nobuhisa Matsuhashi
Honoraria - Abbott Japan; Alfresa Pharma Corporation; Amco; Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; EA Pharma; Eisai; Guardant Health; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Kyowa Kirin; Lilly Japan; MC Medical; Merck KGaA; Miyarisan pharmaceutical; MSD; Novartis; Olympus Marketing, Inc.; Ono Pharmaceutical; Stryker; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Covidien (Inst); e-NA Biotec Inc. (Inst); EPS Corporation (Inst); JMS (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Toray Industries (Inst)
 
Hironaga Satake
Honoraria - Asahi KASEI; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Guardant Health; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Asahi Kasei (Inst); MSD (Inst)
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Hiroki Osumi
Honoraria - Bristol-Myers Squibb Japan; Guardant Health; Lilly; Merck; Merck Serono; Taiho Pharmaceutical
 
Naoya Akazawa
No Relationships to Disclose
 
Toshifumi Yamaguchi
Honoraria - MSD Oncology; Ono pharmaceutical., Co LTD
Consulting or Advisory Role - Daiichi Sankyo Company, Limited
 
Yusuke Suwa
No Relationships to Disclose
 
Takashi Ohta
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; EA Pharma; Lilly Japan; Merck KGaA; Novartis; Taiho Pharmaceutical; Takeda
 
Kiichi Sugimoto
No Relationships to Disclose
 
Naoto Takase
No Relationships to Disclose
 
Tatsuki Ikoma
No Relationships to Disclose
 
Tamotsu Sagawa
No Relationships to Disclose
 
Takeshi Yamada
Research Funding - Taiho Pharmaceutical